Studies Demonstrate Gardasil® Has Long Duration of Protection From HPV Disease

Studies Demonstrate Gardasil® Has Long Duration of Protection From HPV Disease PR Newswire LYON, France, December 6, 2012 LYON, France, December 6, 2012 /PRNewswire/ -- Data represents the largest follow-up available for an HPV vaccine Data from two large, long term follow-up studies continue to show that vaccination with Gardasil offers a long duration of protection from human papillomavirus (HPV) diseases related to HPV types 6, 11, 16 and 18. HPV-related diseases include cervical cancer and genital warts. thThe interim data, presented at the 28 International Papillomavirus Conference (IPV) in Puerto Rico, showed that young [1] [2]women and adolescent girls and boys vaccinated with Gardasil were protected from HPV-related diseases for up [3]to eight years following vaccination. Furthermore, data on immunogenicity (the degree to which an immune response is induced) showed that immune levels remained high for nine years following vaccination. "These latest data show an encouraging trend of continued protection with Gardasil against HPV-related cervical, vaginal and vulvar disease in women through eight years," said Professor Susanne Krüger Kjær, Danish Cancer Society. "These studies provide further evidence for the ongoing efficacy, immunogenicity, and safety of Gardasil." The European studies were conducted in Sweden, Denmark, Norway and Iceland.